- Home
- SPCB vs NRXP Comparison
SPCB vs NRXP Comparison
Compare SPCB & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCB
- NRXP
- Stock Information
- Founded
- SPCB 1988
- NRXP 2015
- Country
- SPCB Israel
- NRXP United States
- Employees
- SPCB N/A
- NRXP N/A
- Industry
- SPCB Semiconductors
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SPCB Technology
- NRXP Health Care
- Exchange
- SPCB Nasdaq
- NRXP Nasdaq
- Market Cap
- SPCB 53.3M
- NRXP 58.5M
- IPO Year
- SPCB N/A
- NRXP N/A
- Fundamental
- Price
- SPCB $8.92
- NRXP $2.32
- Analyst Decision
- SPCB Strong Buy
- NRXP Strong Buy
- Analyst Count
- SPCB 1
- NRXP 4
- Target Price
- SPCB $18.00
- NRXP $29.25
- AVG Volume (30 Days)
- SPCB 192.6K
- NRXP 495.0K
- Earning Date
- SPCB 08-14-2025
- NRXP 08-18-2025
- Dividend Yield
- SPCB N/A
- NRXP N/A
- EPS Growth
- SPCB N/A
- NRXP N/A
- EPS
- SPCB 1.89
- NRXP N/A
- Revenue
- SPCB $27,831,000.00
- NRXP N/A
- Revenue This Year
- SPCB N/A
- NRXP N/A
- Revenue Next Year
- SPCB $29.31
- NRXP $231.16
- P/E Ratio
- SPCB $4.71
- NRXP N/A
- Revenue Growth
- SPCB 2.90
- NRXP N/A
- 52 Week Low
- SPCB $2.55
- NRXP $1.10
- 52 Week High
- SPCB $18.95
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- SPCB 41.23
- NRXP 37.39
- Support Level
- SPCB $8.91
- NRXP $2.40
- Resistance Level
- SPCB $9.38
- NRXP $2.83
- Average True Range (ATR)
- SPCB 0.80
- NRXP 0.22
- MACD
- SPCB -0.10
- NRXP -0.00
- Stochastic Oscillator
- SPCB 3.43
- NRXP 8.70
About SPCB SuperCom Ltd. (Israel)
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.